Brief: Crossject H1 Operating Loss At 5.6 Million Euros

Crossject SA

18/09/2020 16:55

Sept 18 (Reuters) - Crossject SA  74C.F :
    * H1 NET LOSS EUR 5.3 MILLION VERSUS LOSS EUR 5.0 MILLION
YEAR AGO
    * H1 OPERATING LOSS EUR 5.6 MILLION VERSUS LOSS EUR 5.7
MILLION
YEAR AGO
    * H1 OPERATING REVENUE EUR 2.1 MILLION VERSUS EUR 1.9
MILLION YEAR
AGO
    * AT 30 JUNE 2020, CROSSJECT HAD CASH AND CASH EQUIVALENTS
OF €7.3
MILLION, COMPARED WITH €7.9 MILLION AT 31 DECEMBER 2019
    * OUTLOOK: CROSSJECT IS AIMING TO SIGN LICENCES WITH UPFRONT
PAYMENTS IN THE NEAR FUTURE
    * ANTICIPATES ADDITIONAL CASH INFLOWS BETWEEN NOW AND THE
END OF
2020 AND BEGINNING OF 2021 IN FORM OF GRANTS CURRENTLY BEING
CONTRACTED AND COMMERCIAL INCOME FROM EXISTING OR NEW LICENCE
AGREEMENTS
    * CLINICAL BATCHES OF ZENEO MIDAZOLAM WILL SOON BE
FINALISED,
ENABLING LAUNCH OF CLINICAL STUDY AND MANUFACTURE OF VALIDATION
BATCHES

Source text for Eikon:  ID:nGNE6NR78S 
Further company coverage:  74C.F 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))